Clarius OB AI reportedly provides estimates of fetal age, weight and growth intervals based on automated fetal biometry measurements available through handheld ultrasound.
The Food and Drug Administration (FDA) has granted 510(k) clearance for Clarius OB AI, an AI-powered handheld ultrasound tool that may bolster access for use of the technology in monitoring fetal wellbeing.
Trained on over 30,000 fetal ultrasound images, Clarius OB AI automates appropriate caliper placement for the calculation of fetal biometry measurements and enables one to add the measurements to patient electronic medical records through the Clarius app, according to Clarius, the developer of Clarius OB AI.
Trained on over 30,000 fetal ultrasound images, the recently FDA-cleared Clarius OB AI tool automates appropriate caliper placement for the calculation of fetal biometry measurements and enables one to add the measurements to patient electronic medical records through the Clarius app. (Image courtesy of Clarius.)
Carolyn L. Gegor, CNN, MS, FACNM, called the Clarius OB AI tool an “excellent teaching modality” that could help reduce the learning curve with OB ultrasound for those who lack experience with ultrasound scanning.
"When I used Clarius OB AI while teaching OB ultrasound to a group of midwives, I was impressed by the accuracy of cursor placement on multiple scans, from crown rump length to biparietal diameter and femur length," noted Gegor, an ARDMS-certified midwife sonographer. "I found that after using the OB AI model, the students were more able to properly measure structures without the assistance of the AI.”
Clarius noted the Clarius OB AI tool is included with Clarius membership and available in the United States and Canada with the Clarius C3 HD3 handheld ultrasound device.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).